The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

Shares of Gilead Sciences, Inc. (GILD) traded nearly 3% lower in pre-market on Friday after the company reported ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a ...

In a report released yesterday, Matthew Biegler from Oppenheimer maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company ...

Shares of Gilead Sciences Inc. GILD slid 3.66% to $101.40 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 3.46% to ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24 ...

Initiated Phase 1/2 study expansion for IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy ®, Gilead's Trop-2 directed ADC, in MTAP-deletion urothelial cancer based on preliminary ...